ReviewDrugs & aging2017
Pharmacological Management of Allergic Rhinitis in the Elderly.
Review in Drugs & aging, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- Molecular Aspects of Allergen-Specific Immunotherapy in Patients with Seasonal Allergic Rhinitis.Cells · 2023Pooled it
- Identification of Mitochondrial-Related Signature in Allergic Rhinitis: Novel Insights from Bioinformatics and Machine Learning.Journal of inflammation research · 2026Article
- Allergic Rhinitis-Underrepresented Populations and Barriers to Healthcare Access.The Laryngoscope · 2025Article
- Rhinitis in the Geriatric Population: Epidemiological and Cytological Aspects.Geriatrics (Basel, Switzerland) · 2025Review
- Optimizing treatment for older adults with depression.Therapeutic advances in psychopharmacology · 2023Review
- Article
- Article
- Turkish Guideline for Diagnosis and Treatment of Allergic Rhinitis (ART).Turkish archives of otorhinolaryngology · 2021Article
- A Prospective Study to Compare Clinical Outcomes of Allergic Rhinitis Between Older and Younger Adults: A Potential Effect of Depression in Older Patients.Allergy, asthma & immunology research · 2021Article
- Protective effect of Asarum sieboldii essential oil on ovalbumin induced allergic rhinitis in rat.Bioscience reports · 2020Article
- Honeysuckle extract relieves ovalbumin-induced allergic rhinitis by inhibiting AR-induced inflammation and autoimmunity.Bioscience reports · 2019Article
- Efficacy and Safety of Sublingual Immunotherapy in Elderly Rhinitis Patients Sensitized to House Dust Mites.Allergy, asthma & immunology research · 2018Article
- International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis.International forum of allergy & rhinology · 2018Article
- Immunological and non-immunological mechanisms of allergic diseases in the elderly: biological and clinical characteristics.Immunity & ageing : I & A · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent studies suggest that allergic rhinitis is highly prevalent in the elderly population, but is underdiagnosed and undertreated. This review article briefly introduces allergic rhinitis in the elderly (epidemiology and pathophysiology) and identifies the main goals of treatment in these patients with respect to age-related physiological factors, comorbid conditions and polypharmacy. The primary focus of the article is a narrative review of the literature concerning the different types of treatment options in elderly patients aged 60+ years (pharmacological therapy and allergen-specific immunotherapy). The main management trend for allergic rhinitis in elderly patients is the same as the trend in young patients. Second-generation antihistamines and nasal glucocorticosteroids are also the first-line therapies in seniors. In a few trials, allergen-specific immunotherapy for grass pollen or house dust mites has been shown to be effective and safe in patients aged 60 years or older with allergic rhinitis. In conclusion, undertreatment of allergic rhinitis in the elderly is a reality. Pharmacological treatment is quite similar in both older and younger patients with allergic rhinitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.